Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
iTeos Therapeutics, Inc. ITOS
$14.10
+$0.03 (0.21%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
513562424.00000000
-
week52high
28.05
-
week52low
12.52
-
Revenue
267630000
-
P/E TTM
5
-
Beta
1.33216200
-
EPS
2.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 13 дек 2021 г. |
| SVB Leerink | Outperform | Outperform | 12 ноя 2021 г. |
| SVB Leerink | Outperform | Outperform | 13 авг 2021 г. |
| SVB Leerink | Outperform | Outperform | 19 мая 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | A | 17538 | 17538 | 09 июн 2022 г. |
| Van Hauwermeiren Timothy | A | 17538 | 17538 | 09 июн 2022 г. |
| RODEN MATTHEW | A | 17538 | 17538 | 09 июн 2022 г. |
| RHOADS ANN D | A | 17538 | 17538 | 09 июн 2022 г. |
| Hallal David | A | 17538 | 17538 | 09 июн 2022 г. |
| Hallal David | A | 146160 | 1171 | 09 июн 2022 г. |
| Hallal David | A | 147331 | 10577 | 09 июн 2022 г. |
| Hallal David | A | 25140 | 11899 | 09 июн 2022 г. |
| Hallal David | A | 157908 | 5968 | 09 июн 2022 г. |
| Hallal David | D | 0 | 1171 | 09 июн 2022 г. |
Новостная лента
iTeos to Present at SVB Securities Global Biopharma Conference
GlobeNewsWire
07 февр 2023 г. в 07:00
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference being held virtually on Tuesday, February 14, 2023 at 10:00 a.m. EST.
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
InvestorPlace
02 февр 2023 г. в 14:19
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST (11:15 a.m. EST).
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
GlobeNewsWire
22 ноя 2022 г. в 07:00
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Piper Sandler 34th Annual Healthcare Conference in New York City on Tuesday, November 29, 2022 at 4:30 p.m. ET.
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 21:49
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?